Clinical trial · Observational
Longitudinal Investigation of Cancer-related Fatigue
A Prospective, Observational Study to Investigate Longterm Courses, Patterns, Determinants and State of Treatment of Cancer-related Fatigue in Germany (LIFT)
NCT03211273CI-TRIAL-00040290LIFTwithdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): no funding
Summary
Brief summary (as posted)
In the LIFT study 2000 cancer patients will be recruited at 6 months after diagnosis and extensively surveyed over five years on factors that are associated with fatigue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer-related Fatigue | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patient cohort
- description
- Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis. No intervention.
Primary outcomes (3)
- measure
- Fatigue severity
- timeFrame
- from diagnosis to 1 year post-diagnosis
- description
- assessed by EORTC QLQ-FA12 (European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire)
- measure
- Impact of fatigue
- timeFrame
- from diagnosis to 1 year post-diagnosis
- description
- assessed by the Brief Fatigue Inventory (BFI)
- measure
- State of fatigue management
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥ 18 years of age * Diagnosed with a primary tumor of breast, ovarian, or colon cancer * Time since first diagnosis is 4 - 6 months * Having received or currently receiving at least one of the following treatments: surgery, chemotherapy, radiotherapy, hormone therapy, or immune therapy. * Able to understand and follow the study protocol. Exclusion Criteria: • Any additional malignant or unclear neoplasm or carcinoma in situ at or since time of diagnosis of the considered primary tumor
References
Publications (0)
Data not yet available
No reference posted for this study.